Systematic review shows combined Ulinastatin and Tranexamic Acid improves outcomes in cardiac surgery, suggesting effective blood management strategies.
Key Points
This study aims to assess the benefits of combining ulinastatin and tranexamic acid in cardiac surgery compared to monotherapy.
Systematic review of clinical trials identified through multiple databases including PubMed, EMBASE, and Cochrane Library.
Synthesis of data from sixteen studies involving 1,617 subjects using random-effects meta-analysis.
Primary outcomes analyzed were perioperative blood loss and transfusion requirements, with secondary outcomes including coagulation function and complications.
Combination therapy significantly reduced postoperative bleeding volume and RBC transfusion requirements compared to ULI alone (exact numbers not specified).
Significant improvements in prothrombin time, activated partial thromboplastin time, and D-dimer levels were observed with the combination therapy.
No significant adverse events were reported, indicating safety in the combined intervention.